ClinicalTrials.gg
CompletedNCT02734654Updated Mar 3, 2017

Limb RIPC in Patients Undergoing Lung Lobectomy. Study of Oxidative Lung Damage

An interventional study of remote ischemic preconditioning (RIPC) in Acute Lung Injury, sponsored by Instituto de Salud Carlos III. Completed. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-03-03.

Sponsored by Instituto de Salud Carlos III · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Background: In patients undergoing lung lobectomy, lung collapse and re-expansion after resection is associated to severe oxidative lung injury. The researchers hypothesized that remote ischemic preconditioning (RIPC) could reduce oxidative lung injury and improve the oxygenation parameters.

Methods: We designed a single-centre, randomized, prospective and double-blind study, conducted in fifty-three patients with non-small cell lung cancer undergoing elective lung lobectomy.

Fifty-three patients were randomly assigned to 2 groups: 26 patients received limb RIPC (3 cycles: 5 min ischemia/5 min reperfusion induced by an ischemia cuff applied on the thigh) and 27 controls.

Time course of oxidative stress marker levels was simultaneously studied in exhaled breath condensate (EBC) and blood at four specific time points: T0, pre-operatively; T1, during operated lung collapse and one-lung ventilation (OLV); T2, immediately after resuming two-lung ventilation (TLV); T3, 120 min after resuming TLV.

EBC 8-isoprostane was the primary outcome. Secondary outcomes included PaO2/FiO2, other pulmonary oxygenation variables, other oxidative markers (NO2-+NO3-, H2O2) and pH.

Read the detailed description

In patients with non-small-cell lung carcinoma (NSCLC), the surgical resection remains the primary and preferred approach to the treatment of stage I-II NSCLC. Despite advances in surgical techniques, these patients have a risk of development a severe lung injury, because during lobectomy the operated lung is completely collapsed and hypoperfused. This hypoperfusion is due in part to a reactive hypoxic pulmonary vasoconstriction in response to alveolar hypoxia, which optimizes gas exchange. Hypoxic or ischemic tissues increase the reactive oxygen species (ROS) production in mitochondria respiratory chain, because the respiratory cytochromes become redox-reduced allowing them to directly transfer electrons to O2 producing large amount of superoxide anions, which contributes to more vasoconstriction. The primary site of ROS production during hypoxia appears to be complex III, and paradoxical increase of ROS production during hypoxia may be explained by an effect of O2 within mitochondria inner membrane on the ubisemiquinone radical in complex III. Thus, patients undergoing lobar resection suffer a relative lung ischemia-hypoxia during the collapse, followed by expansion-reperfusion injury attributed to the production of ROS. Acute lung injury (ALI) and postoperative adult respiratory distress syndrome (ARDS) after major thoracic surgery remains the leading cause of death from pulmonary surgery. Because to date few studies have assessed this subject in detail, we have showed recently also an increase of oxidative stress damage during lung lobectomy, associated to a direct correlation of lung collapse time with oxidative stress marker levels in exhaled breath condensate and blood.

Remote ischemic preconditioning (RIPC) has emerged as a procedure for different organs protection against acute ischemia/reperfusion injury as is shown by different clinical trials. Although most studies have been conducted in patients undergoing coronary artery by-pass grafting and valvular heart surgery, also were observed protective effect in other organs as kidneys, intestine and others. RIPC is an innate and powerful mechanism where a tissue or organ is exposed to a transient episode of ischemia-reperfusion and then confer a global resistance to subsequent episodes of ischemia in remote organs. However the potential mechanism through which RIPC works is unclear. The signal transfer to organs is through humoral, neuronal and systemic communications, which activate specific receptors, intracellular kinases and mitochondrial function. Recently has been reported that limb RIPC attenuates intestinal and pulmonary injury after abdominal aortic aneurysm repair and also after pulmonary resection, where they found significant decreases in serum malondialdehyde in treated group with RIPC.

EBC collection is non-invasive method for obtain samples from the lower respiratory tract, which contains large number of biomarkers including isoprostanes, nitrogen oxides and hydrogen peroxide. The isoprostanes are a family of products from arachidonic acid produced by the non-enzymatic action of ROS. Increased blood level of 8-isoprostane is considered a reliable index of lipid peroxidation in vivo due to its chemical stability. NO. and superoxide anion (O2.-) react to form ONOO-, which is a powerful oxidant. Nitrites (NO2-) and nitrates (NO3-) are end products of nitric oxide (NO.) and peroxynitrite anion (ONOO-) metabolism and present in the epithelial lining fluid of the respiratory tract. Hydrogen peroxide (H2O2) is a ROS and volatile molecule produced from conversion of superoxide anion (O2.-) to H2O2 by superoxide dismutase and released from inflammatory and epithelial cells of respiratory system.

The aim of this study is to investigate whether RIPC would reduce the oxidative lung injury in cancer patients undergoing lung lobectomy. The primary outcome of this study was compare 8-isoprostene and others oxidative marker levels in EBC and blood between patients receiving RIPC and control patients. Also to evaluate whether there is a correlation between OLV duration and oxidative stress marker levels in EBC and blood.

02

Conditions studied

  • Acute Lung Injury

Browse trials for

Keywords

  • oxidative stress
  • lung lobectomy
03

In context

Acute Lung Injury

382 studies on the registry are indexed under Acute Lung Injury; 73 are open to participants now.

This study's enrollment of 53 is below the median of 60 across 227 interventional studies indexed under Acute Lung Injury.

Browse Acute Lung Injury studies →

Lead sponsor

Instituto de Salud Carlos III is the lead sponsor of 10 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • lung cancer patients (clinical stage I-II NSCLC)
  • elective lung lobectomy
  • patients were randomized and prospectively studied in a single centre
  • all patients were I-II category
  • pregnants

Exclusion criteria

Exclusion Criteria:

  • previous radiotherapy-chemotherapy
  • previous thorax surgery
  • PaO2 \<60 mmHg
  • \<50%
  • cardiac disease ( II-IV)
  • active infections and temperature >37.5 ºC
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
53 participants (actual)

Study arms

  • No intervention
    Control group

    patients do not receive remote preconditioning prior to lung lobectomy

  • Experimental
    RIPC group

    patients receive remote preconditioning prior to lung lobectomy

    Procedure: remote ischemic preconditioning (RIPC)

Interventions

  • Procedureremote ischemic preconditioning (RIPC)

    Remote ischemic preconditioning: The limb RIPC was applied after the induction of anaesthesia and consisted of 3 cycles: 5 min of ischemia by a cuff-inflator on a thigh and inflated to 200 mmHg, followed by 5 min deflated. The control group had during the same time a deflated cuff on a thigh.

06

What researchers measure

Primary outcomes

  1. Time course of 8-isoprostane levels in exhaled breath condensate during and after lung lobectomy

    levels of 8-isoprostane in exhaled breath condensate were measured during lung lobectomy (T0: after anesthesia induction; T1: before two lung ventilation; T3: after two lung ventilation) and 2 hours after lobectomy in critical care unit (T3).

    Time frame: Approximately 4 hours: after anesthesia (T0), during lung lobectomy (T1, T2) and 2 hours after lung lobectomy (T3)

Secondary outcomes

  1. Time course of PO2/FiO2 ratio in arterial blood gas during and after lung lobectomy

    PO2/FiO2 ratio in arterial blood gas during lung lobectomy and during 24 hours in critical care unit

    Time frame: during lung lobectomy (T0, T1, T2) and 24 hours after lung lobectomy in the critical care unit (T3, T4, T5)

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Garcia-de-la-Asuncion J, Garcia-Del-Olmo E, Galan G, Guijarro R, Marti F, Badenes R, Perez-Griera J, Duca A, Delgado C, Carbonell J, Belda J. Glutathione oxidation correlates with one-lung ventilation time and PO2/FiO2 ratio during pulmonary lobectomy. Redox Rep. 2016 Sep;21(5):219-26. doi: 10.1080/13510002.2015.1101890. Epub 2016 Jan 21. Erratum In: Redox Rep. 2017 Mar;22(2):98. doi: 10.1080/13510002.2016.1202057. PubMed 26795138 ↗
  • Misthos P, Katsaragakis S, Theodorou D, Milingos N, Skottis I. The degree of oxidative stress is associated with major adverse effects after lung resection: a prospective study. Eur J Cardiothorac Surg. 2006 Apr;29(4):591-5. doi: 10.1016/j.ejcts.2005.12.027. Epub 2006 Feb 14. PubMed 16476542 ↗
  • Horvath I, Hunt J, Barnes PJ, Alving K, Antczak A, Baraldi E, Becher G, van Beurden WJ, Corradi M, Dekhuijzen R, Dweik RA, Dwyer T, Effros R, Erzurum S, Gaston B, Gessner C, Greening A, Ho LP, Hohlfeld J, Jobsis Q, Laskowski D, Loukides S, Marlin D, Montuschi P, Olin AC, Redington AE, Reinhold P, van Rensen EL, Rubinstein I, Silkoff P, Toren K, Vass G, Vogelberg C, Wirtz H; ATS/ERS Task Force on Exhaled Breath Condensate. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J. 2005 Sep;26(3):523-48. doi: 10.1183/09031936.05.00029705. PubMed 16135737 ↗
  • Przyklenk K, Whittaker P. Remote ischemic preconditioning: current knowledge, unresolved questions, and future priorities. J Cardiovasc Pharmacol Ther. 2011 Sep-Dec;16(3-4):255-9. doi: 10.1177/1074248411409040. PubMed 21821525 ↗
  • Garcia-de-la-Asuncion J, Garcia-del-Olmo E, Perez-Griera J, Marti F, Galan G, Morcillo A, Wins R, Guijarro R, Arnau A, Sarria B, Garcia-Raimundo M, Belda J. Oxidative lung injury correlates with one-lung ventilation time during pulmonary lobectomy: a study of exhaled breath condensate and blood. Eur J Cardiothorac Surg. 2015 Sep;48(3):e37-44. doi: 10.1093/ejcts/ezv207. Epub 2015 Jun 18. PubMed 26088589 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 3, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02734654
Lead sponsor
Instituto de Salud Carlos III
Responsible party
José García de la Asunción (MD, PhD, Instituto de Salud Carlos III) — Principal investigator
First posted
Apr 12, 2016
Start date
Nov 2007
Primary completion
Feb 2011
Completion
Jan 2012
Last update
Mar 3, 2017

Study contacts

José García de la Asunción, MD, PhD
principal investigator · Instituto de Investigador Sanitaria, INCLIVA

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion